News & Updates

A third-dose administration of a COVID-19 mRNA vaccine results in a more substantial decrease in COVID-19 in patients with cirrhosis compared with the general population, according to a study. This suggests that the third dose can overcome vaccine hyporesponsiveness in this population.

Treatment with dulaglutide is both effective and safe in Asians with type 2 diabetes mellitus (T2DM), a recent meta-analysis has found.

The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.

Switching to the once-a-day, fixed-dose pill that contains bictegravir, emtricitabine, and tenofovir (BIC/FTC/TAF) appears to be safe and effective in older HIV patients and in people living with HIV (PLHIV) with pretreatment or treatment-acquired resistance, in addition to yielding metabolic benefits, according to studies presented at HIV Glasgow 2022.